Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab

A woman in her 70s presented with gallbladder carcinoma with liver metastases and peritoneal dissemination. After standard chemotherapy failed, a liver biopsy was performed. A FoundationOne CDx analysis showed that the tumor mutational burden (TMB) was high (34 mutations/megabase). Treatment with pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Uehara, Sanae, Naganuma, Atsushi, Furuichi, Nozomi, Furusawa, Ai, Kaburagi, Takuya, Naruse, Hiroaki, Tomaru, Shota, Sano, Nozomi, Suzuki, Yuhei, Masuda, Tomoyuki, Hoshino, Takashi, Yasuoka, Hidetoshi, Tanaka, Yuko, Saito, Shuichi, Hatanaka, Takeshi, Kakizaki, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686744/
https://www.ncbi.nlm.nih.gov/pubmed/36927965
http://dx.doi.org/10.2169/internalmedicine.1610-23
_version_ 1785151830091628544
author Uehara, Sanae
Naganuma, Atsushi
Furuichi, Nozomi
Furusawa, Ai
Kaburagi, Takuya
Naruse, Hiroaki
Tomaru, Shota
Sano, Nozomi
Suzuki, Yuhei
Masuda, Tomoyuki
Hoshino, Takashi
Yasuoka, Hidetoshi
Tanaka, Yuko
Saito, Shuichi
Hatanaka, Takeshi
Kakizaki, Satoru
author_facet Uehara, Sanae
Naganuma, Atsushi
Furuichi, Nozomi
Furusawa, Ai
Kaburagi, Takuya
Naruse, Hiroaki
Tomaru, Shota
Sano, Nozomi
Suzuki, Yuhei
Masuda, Tomoyuki
Hoshino, Takashi
Yasuoka, Hidetoshi
Tanaka, Yuko
Saito, Shuichi
Hatanaka, Takeshi
Kakizaki, Satoru
author_sort Uehara, Sanae
collection PubMed
description A woman in her 70s presented with gallbladder carcinoma with liver metastases and peritoneal dissemination. After standard chemotherapy failed, a liver biopsy was performed. A FoundationOne CDx analysis showed that the tumor mutational burden (TMB) was high (34 mutations/megabase). Treatment with pembrolizumab, which is an immune checkpoint inhibitor (ICI), resulted in a partial response, and there were no significant immune-related adverse events. According to recently published reports, the frequency of TMB-high biliary tract cancer (BTC) is 3.4-4%, which makes it extremely rare. In conclusion, ICIs may be effective in patients with TMB-high BTC.
format Online
Article
Text
id pubmed-10686744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-106867442023-11-30 Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab Uehara, Sanae Naganuma, Atsushi Furuichi, Nozomi Furusawa, Ai Kaburagi, Takuya Naruse, Hiroaki Tomaru, Shota Sano, Nozomi Suzuki, Yuhei Masuda, Tomoyuki Hoshino, Takashi Yasuoka, Hidetoshi Tanaka, Yuko Saito, Shuichi Hatanaka, Takeshi Kakizaki, Satoru Intern Med Case Report A woman in her 70s presented with gallbladder carcinoma with liver metastases and peritoneal dissemination. After standard chemotherapy failed, a liver biopsy was performed. A FoundationOne CDx analysis showed that the tumor mutational burden (TMB) was high (34 mutations/megabase). Treatment with pembrolizumab, which is an immune checkpoint inhibitor (ICI), resulted in a partial response, and there were no significant immune-related adverse events. According to recently published reports, the frequency of TMB-high biliary tract cancer (BTC) is 3.4-4%, which makes it extremely rare. In conclusion, ICIs may be effective in patients with TMB-high BTC. The Japanese Society of Internal Medicine 2023-03-15 2023-11-01 /pmc/articles/PMC10686744/ /pubmed/36927965 http://dx.doi.org/10.2169/internalmedicine.1610-23 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Uehara, Sanae
Naganuma, Atsushi
Furuichi, Nozomi
Furusawa, Ai
Kaburagi, Takuya
Naruse, Hiroaki
Tomaru, Shota
Sano, Nozomi
Suzuki, Yuhei
Masuda, Tomoyuki
Hoshino, Takashi
Yasuoka, Hidetoshi
Tanaka, Yuko
Saito, Shuichi
Hatanaka, Takeshi
Kakizaki, Satoru
Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
title Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
title_full Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
title_fullStr Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
title_full_unstemmed Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
title_short Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
title_sort successful treatment of metastatic gallbladder carcinoma with a high tumor mutational burden using pembrolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686744/
https://www.ncbi.nlm.nih.gov/pubmed/36927965
http://dx.doi.org/10.2169/internalmedicine.1610-23
work_keys_str_mv AT ueharasanae successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT naganumaatsushi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT furuichinozomi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT furusawaai successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT kaburagitakuya successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT narusehiroaki successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT tomarushota successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT sanonozomi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT suzukiyuhei successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT masudatomoyuki successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT hoshinotakashi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT yasuokahidetoshi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT tanakayuko successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT saitoshuichi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT hatanakatakeshi successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab
AT kakizakisatoru successfultreatmentofmetastaticgallbladdercarcinomawithahightumormutationalburdenusingpembrolizumab

Ejemplares similares